Novartis Earlier Launched New $11B Share Buyback Program
-Reuters
https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-launches-new-share-buyback-up-10-its-stock-2023-03-13/
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
Novartis AG (NYSE:NVS) has decided to terminate the Collaboration and License Agreement with Pliant Therapeutics, Inc.(NASDAQ:PLRX), announced in 2019. Novartis told…
Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off
Novartis AG (NYSE:NVS) has reported Q4 core EPS of $1.52 compared to $1.40 a year ago, beating the consensus of $1.44.…
Novartis Q4 Core EPS $1.52 Beats $1.44 Estimate, Sales $12.69B Miss $13.13B Estimate
Novartis (NYSE:NVS) reported quarterly earnings of $1.52 per share which beat the analyst consensus estimate of $1.44 by 5.56 percent. This is a 8.57 percent increase over earnings of $1.40 per share from the same period
A Preview Of Novartis’s Earnings
Novartis (NYSE:NVS) is set to give its latest quarterly earnings report on Wednesday, 2023-02-01. Here’s what investors need…
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.